Cipla has received final approval for its ANDA for darifenacin extended-release tablets, 7.5mg and 15mg, from the US FDA.
Darifenacin extended-release tablets, 7.5mg and 15mg, are AB-rated generic equivalents of Allergan’s Enablex tablets, 7.5mg and 15mg, and are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. The product will be launched immediately.
Enablex tablets and generic equivalents had US sales of approximately $85 million for the 12 month period ending June 2016, according to IMS Health.
Subscribe to PharmaTutor News Alerts by Email
